Steroid hormone action in musculoskeletal cells involves membrane receptor and nuclear receptor mechanisms.
Steroid hormones regulate target cells through traditional nuclear mechanisms as well as by membrane mechanisms. 1alpha,25(OH)2D3 and 24R,25(OH)2D3 bind membrane receptors (mVDR) and mediate their effects on the physiological responses of musculoskeletal cells via protein kinase C (PKC). In cultures of costochondral growth plate chondrocytes, 1alpha,25(OH)2D3 binds the 1,25-mVDR in growth zone cells, activating phospholipase C (PLC), leading to diacylglycerol (DAG) production and PKC translocation to the plasma membrane. It also activates PLA2, increasing arachidonic acid release and prostaglandin synthesis. 24R,25(OH)2D3 binds its membrane receptor in resting zone chondrocytes, activating phospholipase D (PLD), and increasing DAG and PKC activity, but translocation does not occur. PLA2 activity is decreased, reducing arachidonic acid and prostaglandin production. 17Beta-estradiol (E2) activates PKC in both cartilage cells, but DAG is not involved. 1alpha,25(OH)2D3 and 24R,25(OH)2D3 also increase PKC in osteoblasts in a cell-specific manner. Antibodies to the 1,25-mVDR block PKC activation. Membrane-mediated events influence gene expression via signaling cascades, including the ERK1/2 MAP kinases. The ability of steroid hormones to initiate events nongenomically is important for regulation of matrix vesicle (MV) function in the extracellular matrix. MVs have mVDRs, but ligand binding inhibits PKC-zeta (PKCzeta) via a mechanism that differs from PKCalpha activation in the plasma membranes. Treatment of MVs from growth zone chondrocyte cultures with 1alpha,25(OH)2D3 releases stromelysin-1 (MMP-3) and increases TGF-beta activation. MMP-3 is also involved in proteoglycan degradation, facilitating calcification. 24R,25(OH)2D3 inhibits PKCzeta in MV from resting zone cell cultures and inhibits MMP-3 release. Chondrocytes and osteoblasts produce 1,25(OH)2D3, 24,25(OH)2D3, and E2; thus, locally produced steroids may function as autocrine regulators of matrix events, including matrix vesicle enzyme activity and matrix protein remodelling during longitudinal growth, calcification, and growth factor activation.
Boyan
Barbara D
BD
Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, Georgia 30332, USA. BarbaraBoyan@ubme.gatech.edu
Dean
David D
DD
Sylvia
Victor L
VL
Schwartz
Zvi
Z
D015650:24,25-Dihydroxyvitamin D 3 / Q000378:metabolism*; D000818:Animals; D002478:Cells, Cultured; D003239:Connective Tissue Cells / Q000166:cytology / Q000378:metabolism*; D004100:Dihydroxycholecalciferols / Q000378:metabolism*; D006801:Humans; D051381:Rats; D018167:Receptors, Calcitriol / Q000378:metabolism*; D015398:Signal Transduction
D004100:Dihydroxycholecalciferols; D018167:Receptors, Calcitriol; D015650:24,25-Dihydroxyvitamin D 3; C023850:1 alpha,24-dihydroxyvitamin D3